OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Levine on Immunotherapy for Endometrial Cancer

September 19th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

September 19th 2017

John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

Dr. McGregor Discusses the Future of Treatment for RCC

September 19th 2017

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.

Dr. Bauml Discusses the FLAURA Study in NSCLC

September 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

September 19th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer

September 18th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Dr. Esteva on Next-Generation Sequencing in Metastatic Breast Cancer

September 8th 2017

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.

Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer

September 8th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Christian Downs on the 34th National Oncology Conference

September 8th 2017

Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers (ACCC), discusses the upcoming 34th National Oncology Conference, taking place October 18 to 20 in Nashville, Tennessee.

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

September 8th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Campbell Discusses the Goals of the New RCC Guidelines

September 8th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Dr. Ross Discusses the Future Treatment Landscape of Melanoma

September 8th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the future treatment landscape of melanoma.

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

September 8th 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Dr. Argiles Discusses the Role of Immunotherapy in CRC

September 8th 2017

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer.

Dr. Hu on Active Surveillance for Prostate Cancer

September 8th 2017

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.

Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Dr. Usmani on Potential of Checkpoint Inhibitors in Multiple Myeloma

September 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.

Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL

September 7th 2017

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer

September 7th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.